Cargando…
Novel Heat Shock Protein 90 Inhibitors Suppress P-Glycoprotein Activity and Overcome Multidrug Resistance in Cancer Cells
Heat Shock Protein 90 (Hsp90) chaperone interacts with a broad range of client proteins involved in cancerogenesis and cancer progression. However, Hsp90 inhibitors were unsuccessful as anticancer agents due to their high toxicity, lack of selectivity against cancer cells and extrusion by membrane t...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770006/ https://www.ncbi.nlm.nih.gov/pubmed/31527404 http://dx.doi.org/10.3390/ijms20184575 |
_version_ | 1783455370282270720 |
---|---|
author | Dinić, Jelena Podolski-Renić, Ana Jovanović, Mirna Musso, Loana Tsakovska, Ivanka Pajeva, Ilza Dallavalle, Sabrina Pešić, Milica |
author_facet | Dinić, Jelena Podolski-Renić, Ana Jovanović, Mirna Musso, Loana Tsakovska, Ivanka Pajeva, Ilza Dallavalle, Sabrina Pešić, Milica |
author_sort | Dinić, Jelena |
collection | PubMed |
description | Heat Shock Protein 90 (Hsp90) chaperone interacts with a broad range of client proteins involved in cancerogenesis and cancer progression. However, Hsp90 inhibitors were unsuccessful as anticancer agents due to their high toxicity, lack of selectivity against cancer cells and extrusion by membrane transporters responsible for multidrug resistance (MDR) such as P-glycoprotein (P-gp). Recognizing the potential of new compounds to inhibit P-gp function and/or expression is essential in the search for effective anticancer drugs. Eleven Hsp90 inhibitors containing an isoxazolonaphtoquinone core were synthesized and evaluated in two MDR models comprised of sensitive and corresponding resistant cancer cells with P-gp overexpression (human non-small cell lung carcinoma and colorectal adenocarcinoma). We investigated the effect of Hsp90 inhibitors on cell growth inhibition, P-gp activity and P-gp expression. Structure–activity relationship analysis was performed in respect to cell growth and P-gp inhibition. Compounds 5, 7, and 9 directly interacted with P-gp and inhibited its ATPase activity. Their potential P-gp binding site was identified by molecular docking studies. In addition, these compounds downregulated P-gp expression in MDR colorectal carcinoma cells, showed good relative selectivity towards cancer cells, while compound 5 reversed resistance to doxorubicin and paclitaxel in concentration-dependent manner. Therefore, compounds 5, 7 and 9 could be promising candidates for treating cancers with P-gp overexpression. |
format | Online Article Text |
id | pubmed-6770006 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-67700062019-10-30 Novel Heat Shock Protein 90 Inhibitors Suppress P-Glycoprotein Activity and Overcome Multidrug Resistance in Cancer Cells Dinić, Jelena Podolski-Renić, Ana Jovanović, Mirna Musso, Loana Tsakovska, Ivanka Pajeva, Ilza Dallavalle, Sabrina Pešić, Milica Int J Mol Sci Article Heat Shock Protein 90 (Hsp90) chaperone interacts with a broad range of client proteins involved in cancerogenesis and cancer progression. However, Hsp90 inhibitors were unsuccessful as anticancer agents due to their high toxicity, lack of selectivity against cancer cells and extrusion by membrane transporters responsible for multidrug resistance (MDR) such as P-glycoprotein (P-gp). Recognizing the potential of new compounds to inhibit P-gp function and/or expression is essential in the search for effective anticancer drugs. Eleven Hsp90 inhibitors containing an isoxazolonaphtoquinone core were synthesized and evaluated in two MDR models comprised of sensitive and corresponding resistant cancer cells with P-gp overexpression (human non-small cell lung carcinoma and colorectal adenocarcinoma). We investigated the effect of Hsp90 inhibitors on cell growth inhibition, P-gp activity and P-gp expression. Structure–activity relationship analysis was performed in respect to cell growth and P-gp inhibition. Compounds 5, 7, and 9 directly interacted with P-gp and inhibited its ATPase activity. Their potential P-gp binding site was identified by molecular docking studies. In addition, these compounds downregulated P-gp expression in MDR colorectal carcinoma cells, showed good relative selectivity towards cancer cells, while compound 5 reversed resistance to doxorubicin and paclitaxel in concentration-dependent manner. Therefore, compounds 5, 7 and 9 could be promising candidates for treating cancers with P-gp overexpression. MDPI 2019-09-16 /pmc/articles/PMC6770006/ /pubmed/31527404 http://dx.doi.org/10.3390/ijms20184575 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Dinić, Jelena Podolski-Renić, Ana Jovanović, Mirna Musso, Loana Tsakovska, Ivanka Pajeva, Ilza Dallavalle, Sabrina Pešić, Milica Novel Heat Shock Protein 90 Inhibitors Suppress P-Glycoprotein Activity and Overcome Multidrug Resistance in Cancer Cells |
title | Novel Heat Shock Protein 90 Inhibitors Suppress P-Glycoprotein Activity and Overcome Multidrug Resistance in Cancer Cells |
title_full | Novel Heat Shock Protein 90 Inhibitors Suppress P-Glycoprotein Activity and Overcome Multidrug Resistance in Cancer Cells |
title_fullStr | Novel Heat Shock Protein 90 Inhibitors Suppress P-Glycoprotein Activity and Overcome Multidrug Resistance in Cancer Cells |
title_full_unstemmed | Novel Heat Shock Protein 90 Inhibitors Suppress P-Glycoprotein Activity and Overcome Multidrug Resistance in Cancer Cells |
title_short | Novel Heat Shock Protein 90 Inhibitors Suppress P-Glycoprotein Activity and Overcome Multidrug Resistance in Cancer Cells |
title_sort | novel heat shock protein 90 inhibitors suppress p-glycoprotein activity and overcome multidrug resistance in cancer cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770006/ https://www.ncbi.nlm.nih.gov/pubmed/31527404 http://dx.doi.org/10.3390/ijms20184575 |
work_keys_str_mv | AT dinicjelena novelheatshockprotein90inhibitorssuppresspglycoproteinactivityandovercomemultidrugresistanceincancercells AT podolskirenicana novelheatshockprotein90inhibitorssuppresspglycoproteinactivityandovercomemultidrugresistanceincancercells AT jovanovicmirna novelheatshockprotein90inhibitorssuppresspglycoproteinactivityandovercomemultidrugresistanceincancercells AT mussoloana novelheatshockprotein90inhibitorssuppresspglycoproteinactivityandovercomemultidrugresistanceincancercells AT tsakovskaivanka novelheatshockprotein90inhibitorssuppresspglycoproteinactivityandovercomemultidrugresistanceincancercells AT pajevailza novelheatshockprotein90inhibitorssuppresspglycoproteinactivityandovercomemultidrugresistanceincancercells AT dallavallesabrina novelheatshockprotein90inhibitorssuppresspglycoproteinactivityandovercomemultidrugresistanceincancercells AT pesicmilica novelheatshockprotein90inhibitorssuppresspglycoproteinactivityandovercomemultidrugresistanceincancercells |